BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 22940055)

  • 21. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
    Pardal E; Coronado M; Martín A; Grande C; Marín-Niebla A; Panizo C; Bello JL; Conde E; Hernández MT; Arranz R; Bargay J; González-Barca E; Pérez-Ceballos E; Montes-Moreno S; Caballero MD
    Br J Haematol; 2014 Nov; 167(3):327-36. PubMed ID: 25066542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.
    Kruger PC; Cooney JP; Turner JH
    Cancer Biother Radiopharm; 2012 Nov; 27(9):552-60. PubMed ID: 23062193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
    Krishnan A; Nademanee A; Fung HC; Raubitschek AA; Molina A; Yamauchi D; Rodriguez R; Spielberger RT; Falk P; Palmer JM; Forman SJ
    J Clin Oncol; 2008 Jan; 26(1):90-5. PubMed ID: 18025438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.
    Winter JN; Inwards DJ; Spies S; Wiseman G; Patton D; Erwin W; Rademaker AW; Weitner BB; Williams SF; Tallman MS; Micallef I; Mehta J; Singhal S; Evens AM; Zimmer M; Molina A; White CA; Gordon LI
    J Clin Oncol; 2009 Apr; 27(10):1653-9. PubMed ID: 19255322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease.
    Argiris A; Seropian S; Cooper DL
    Ann Oncol; 2000 Jun; 11(6):665-72. PubMed ID: 10942053
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.
    Jo JC; Kang BW; Jang G; Sym SJ; Lee SS; Koo JE; Kim JW; Kim S; Huh J; Suh C
    Ann Hematol; 2008 Jan; 87(1):43-8. PubMed ID: 17710401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
    Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. (90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study.
    Decaudin D; Mounier N; Tilly H; Ribrag V; Ghesquières H; Bouabdallah K; Morschhauser F; Coiffier B; Le Gouill S; Bologna S; Delarue R; Huynh A; Bosly A; Brière J; Gisselbrecht C
    Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):212-8. PubMed ID: 21575926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study.
    Hagberg H; Gisselbrecht C;
    Ann Oncol; 2006 May; 17 Suppl 4():iv31-2. PubMed ID: 16702182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
    Mikesch JH; Kuhlmann M; Demant A; Krug U; Thoennissen GB; Schmidt E; Kessler T; Schliemann C; Pohlen M; Mohr M; Evers G; Köhler G; Wessling J; Mesters R; Müller-Tidow C; Berdel WE; Thoennissen NH
    Ann Hematol; 2013 Aug; 92(8):1041-8. PubMed ID: 23532626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation.
    Jagadeesh D; Majhail NS; He Y; Ahn KW; Litovich C; Ahmed S; Aljurf M; Bacher U; Badawy SM; Bejanyan N; Cairo M; Cerny J; Epperla N; Farhadfar N; Freytes CO; Gale RP; Haverkos B; Hossain N; Inwards D; Kamble RT; Kenkre VP; Lazarus HM; Lazaryan A; Lekakis L; Mei M; Murthy HS; Mussetti A; Nathan S; Nishihori T; Olsson RF; Ramakrishnan Geethakumari P; Savani BN; Yared JA; Fenske TS; Kharfan-Dabaja MA; Sureda A; Hamadani M
    Cancer; 2020 May; 126(10):2279-2287. PubMed ID: 32049359
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study.
    Vitolo U; Chiappella A; Angelucci E; Rossi G; Liberati AM; Cabras MG; Botto B; Ciccone G; Gaidano G; Falchi L; Freilone R; Novero D; Orsucci L; Pavone V; Pogliani E; Rota-Scalabrini D; Salvi F; Tonso A; Tucci A; Levis A;
    Haematologica; 2009 Sep; 94(9):1250-8. PubMed ID: 19586937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma.
    Liu HW; Seftel MD; Rubinger M; Szwajcer D; Demers A; Nugent Z; Schroeder G; Butler JB; Cooke A
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):513-20. PubMed ID: 20137862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma.
    Leger C; Sabloff M; McDiarmid S; Bence-Bruckler I; Atkins H; Bredeson C; Zhang H; Huebsch L
    Ann Hematol; 2006 Oct; 85(10):723-9. PubMed ID: 16832675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intensive therapy and autotransplantation in Hodgkin's disease.
    Reece DE; Phillips GL
    Stem Cells; 1994 Sep; 12(5):477-93. PubMed ID: 7804123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial.
    Deconinck E; Lamy T; Foussard C; Gaillard F; Delwail V; Colombat P; Casassus P; Lemevel A; Brion A; Milpied N
    Br J Haematol; 2000 Jun; 109(4):736-42. PubMed ID: 10929023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group.
    Redondo AM; Valcárcel D; González-Rodríguez AP; Suárez-Lledó M; Bello JL; Canales M; Gayoso J; Colorado M; Jarque I; Del Campo R; Arranz R; Terol MJ; Rifón JJ; Rodríguez MJ; Ramírez MJ; Castro N; Sánchez A; López-Jiménez J; Montes-Moreno S; Briones J; López A; Palomera L; López-Guillermo A; Caballero D; Martín A;
    Br J Haematol; 2019 Mar; 184(5):797-807. PubMed ID: 30548583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zevalin and BEAM (Z-BEAM) versus rituximab and BEAM (R-BEAM) conditioning chemotherapy prior to autologous stem cell transplantation in patients with mantle cell lymphoma.
    Berger MD; Branger G; Klaeser B; Taleghani BM; Novak U; Banz Y; Mueller BU; Pabst T
    Hematol Oncol; 2016 Sep; 34(3):133-9. PubMed ID: 25689832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results.
    Chamoun K; Milton DR; Ledesma C; Young KH; Jabbour EJ; Alatrash G; Anderlini P; Bashir Q; Ciurea SO; Marin D; Molldrem JJ; Olson AL; Oran B; Popat UR; Rondon G; Champlin RE; Gulbis AM; Khouri IF
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1347-1354. PubMed ID: 30826465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
    Fernández-Jiménez MC; Canales MA; Ojeda E; de Bustos JG; Aguado MJ; Hernández-Navarro F
    Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.